SVANasdaqPharmaceutical PreparationsFiscal year ends December 31
SINOVAC BIOTECH LTD
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 5, 2026
$6.47+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- 850.08%
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
67.9%−19.0 pts over 5 years
Operating margin
-127.0%−169.2 pts over 5 years
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +6.8% | -36.0% | -5.4% | +19.1% | |
| Gross profit | +18.7% | -31.5% | -10.0% | +18.3% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -0.5% | 21.2% | – | |
| Return on assets | -0.3% | 9.4% | – | |
| Current ratio | 1.97 | 2.30 | 4.59 | |
| Inventory turnover | 1.4× | 1.0× | 1.3× | |
| Capex to revenue | 17.5% | 0.0% | 12.7% | |
| Diluted shares | 57M | 114M | 72M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Sinovac Biotech generated $16.83B from operations and spent $8.14B on capital expenditure, dividends and share buybacks. 15% of that went back into the business.
Generated
$16.83B
Used
$8.14B
Capital expenditure$1.21B15%Dividends$6.93B85%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-2.9%
×Asset turnover0.03×
×Equity multiplier1.64×
=Return on equity, FY2023-0.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2023 | -2.9% | 0.03× | 1.64× | -0.2% |
| FY2022 | 1.0% | 0.10× | 1.76× | 0.2% |
| FY2021 | 41.9% | 2.08× | 1.92× | 166.8% |
| FY2020 | 21.6% | 0.43× | 2.26× | 21.2% |
| FY2019 | 18.3% | 0.60× | 1.50× | 16.4% |
| FY2018 | 9.5% | 0.69× | 1.65× | 10.8% |
| FY2017 | 14.8% | 0.68× | 1.91× | 19.3% |
| FY2016 | -0.8% | 0.35× | 1.74× | -0.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 5 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-$512.18M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-$512.18M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose7.33 → 4.59
- No dilutionShare count did not rise72M → 72M
- Gross margin improvedGross margin up on the prior year61.07% → 67.87%
- More efficientAsset turnover rose0.03 → 0.03